Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
medline:
29
11
2023
pubmed:
27
1
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
This study investigates the use of serum DUPAN-2 in predicting the PC progression in CA19-9 nonsecretors. Although we previously reported that serum CA19-9 >500U/ mL is a poor prognostic factor and an indication for enhanced neoadjuvant treatment, there is not a biomarker surrogate that equivalently predicts prognosis for CA19-9 nonsecretors. We evaluated consecutive PC patients who underwent pancreatectomy from 2005 to 2019. All patients were categorized as either nonsecretor or secretor (CA19-9 ≤ or >2.0U/mL). Of the 984 resected PC patients, 94 (9.6%) were nonsecretors and 890 (90.4%) were secretors. The baseline characteristics were not statistically different between the 2 groups except for the level of DUPAN-2 (720 vs. 100U/mL, P < 0.001). Survival curves after resection were similar between the 2 groups (29.4 months vs. 31.3 months, P = 0.900). Survival curves of patients with DUPAN-2 >2000U/mL in the nonsecretors and patients with CA19-9 >500U/mL in the secretors were nearly equivalent as well (hazard ratio 2.08 vs. 1.89). In the multivariate analysis, DUPAN-2 >2000U/mL (hazard ratio 2.53, P = 0.010) was identified as independent prognostic factor after resection. DUPAN-2 >2000U/mL in CA19-9 nonsecretors can be an unfavorable factor that corresponds to CA19-9 >500U/mL in CA19-9 secretors which is an indicator for enhanced neoadjuvant treatment. The current results shed light on the subset of nonsecretors with poor prognosis that were traditionally categorized in a group with a more favorable prognosis group.
Sections du résumé
OBJECTIVE
OBJECTIVE
This study investigates the use of serum DUPAN-2 in predicting the PC progression in CA19-9 nonsecretors.
BACKGROUND
BACKGROUND
Although we previously reported that serum CA19-9 >500U/ mL is a poor prognostic factor and an indication for enhanced neoadjuvant treatment, there is not a biomarker surrogate that equivalently predicts prognosis for CA19-9 nonsecretors.
METHODS
METHODS
We evaluated consecutive PC patients who underwent pancreatectomy from 2005 to 2019. All patients were categorized as either nonsecretor or secretor (CA19-9 ≤ or >2.0U/mL).
RESULTS
RESULTS
Of the 984 resected PC patients, 94 (9.6%) were nonsecretors and 890 (90.4%) were secretors. The baseline characteristics were not statistically different between the 2 groups except for the level of DUPAN-2 (720 vs. 100U/mL, P < 0.001). Survival curves after resection were similar between the 2 groups (29.4 months vs. 31.3 months, P = 0.900). Survival curves of patients with DUPAN-2 >2000U/mL in the nonsecretors and patients with CA19-9 >500U/mL in the secretors were nearly equivalent as well (hazard ratio 2.08 vs. 1.89). In the multivariate analysis, DUPAN-2 >2000U/mL (hazard ratio 2.53, P = 0.010) was identified as independent prognostic factor after resection.
CONCLUSION
CONCLUSIONS
DUPAN-2 >2000U/mL in CA19-9 nonsecretors can be an unfavorable factor that corresponds to CA19-9 >500U/mL in CA19-9 secretors which is an indicator for enhanced neoadjuvant treatment. The current results shed light on the subset of nonsecretors with poor prognosis that were traditionally categorized in a group with a more favorable prognosis group.
Identifiants
pubmed: 35081567
doi: 10.1097/SLA.0000000000005395
pii: 00000658-900000000-93098
doi:
Substances chimiques
CA-19-9 Antigen
0
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1278-e1283Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
ObaADel ChiaroMSatoiS . New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29:725–731.
UnnoMMotoiFMatsuyamaY . Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 2019;37(Suppl 4):189–1189.
InoueYSaiuraAObaA . Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2020;28:143–155.
TrutyMJKendrickMLNagorneyDM . Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021;273:341–349.
UshidaYInoueYItoH . High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021;21:130–137.
IsajiSMizunoSWindsorJA . International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.
HaymanAVStockerSJBakerMS . CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol. 2014;37:550–554.
ObaACroceCHosokawaP . Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines. Ann Surg. 2020;275:175–181.
LuoGFanZChengH . New observations on the utility of CA19–9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971–976.
BergerACMeszoelyIMRossEA . Undetectable preoperative levels of serum CA 19–9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644–649.
HartwigWStrobelOHinzU . CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188–2196.
GarceaGLadwaNNealCP . Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease–free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868–872.
NetworkNCC. Pancreatic Adenocarcinoma (Version 3.2019) 2019. Accessed July 2, 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .
ProctorMJMorrisonDSTalwarD . An inflammation–based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–734.
GrootVPRezaeeNWuW . Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–945.
LuoGLiuCGuoM . Potential biomarkers in lewis negative patients with pancreatic cancer. Ann Surg. 2017;265:800–805.
KawaSOguchiHKobayashiT . Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer. 1991;64:899–902.
KawaSTokooMOguchiH . Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 1994;9:692–697.
ObaAInoueYOnoY . Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbecks Arch Surg. 2019;405:35–41.
ObaAInoueYOnoY . Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Br J Surg. 2021;108:115–118.
HackertTSachsenmaierMHinzU . Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264:457–463.
MichelakosTPergoliniICastilloCF . Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269:733–740.
DreyerSBPineseMJamiesonNB . Precision oncology in surgery: patient selection for operable pancreatic cancer. Ann Surg. 2020;272:366–376.